99%+ Purity Progesterone Hormone Steroid Powder Levonorgestrel
Product Details:
| Levonorgestrel Powder Information | ||
| Levonorgestrel Price | 100g | According to your needs |
| 500g | According to your needs | |
| 1000g | According to your needs | |
| Steroid packaging | Special stealth packaging through Customs | |
| Delivery time | About 7 days | |
| Shipping | EMS, Hongkong Post, DHL, TNT, Fedex | |
| Payment terms | WU, MG, Bitcoin, T/T | |
| Minimum order | 10g powder | |
99%+ Purity Progesterone Hormone Steroid Powder Levonorgestrel
Levonorgestrel Details:
Product name: D (minus) -norgestrel
Synonyms: Levonorgestrel; Norgestrel (L-)
CAS: 797-63-7
EINECS Number: 212-349-8
Formula: C21H28O2
Molecular Weight: 312.45
Density: 1.13g / cm3
Melting point: 206 ℃
Boiling point: 459.1 ° C at 760 mmHg
Flash Point: 195.4 ° C
Vapor Pressure: 2.32E-10mmHg at 25 ° C
Uses:Progesterone medicines for irregular menstruation, uterine functional bleeding, endometriosis, etc.
Assay: 99%
Appearance: White crystalline powder
Levonorgestrel Specifications:
COA
Items | Specification | Results |
Description | White or practically white crystalline powder | White crystalline powder |
Specific Rotation | 30°~-35° | 32° |
Melting Range | 232~239°C, and melting range is not more then 4°C | 234~238°C |
identification | It complies with the test for specific optical rotation and melting point | Conforms |
Infrared absorption spectrophotometry should be consistent with levonorgestrel CRS | Conforms | |
Loss on drying | ≤0.5% | 0.20% |
Residue on ignition | ≤0.3% | 0.07% |
Limit of Ethynyl Group | 7.81%~8.18% | 7.92% |
Related substances | Single impurity ≤0.5% | single impurity<0.5% |
Total Impurities ≤2.0% | Total impurities<2.0% | |
Organic Volatile impurties | Ethanol ≤5000ppm | 1200ppm |
Assay | The product complies with specification in USP34 | |
Particle Size | D(0.9)<10μm | |
Storage Condition | Sealed, protect from light | |
Levonorgestrel Descriptions:
Levonorgestrel (or l-norgestrel or D-norgestrel) (Plan B, Next Choice, Postinor, "the morning after pill," and others) is a second generation progestin (synthetic progestogen) used as an active ingredient in some hormonal contraceptives, includingcombined oral contraceptive pills, progestogen only pills, emergency contraceptive pills, intrauterine systems, contraceptive implants, and hormone replacement therapy.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basichealth system.
Levonorgestrel Usage:
Oral contraception
At low doses, levonorgestrel is used in monophasicand triphasicformulations of combined oral contraceptive pills, with available monophasic doses ranging from 100-250μg, and triphasic doses of 50μg/75μg/125μg.
At very low daily dose of 30μg, levonorgestrel is used in some progestogen only pillformulations.
Emergency contraception
Levonorgestrel is used in emergency contraceptive pills(ECPs), both in a combined Yuzpe regimenwhich includes estrogen, and as a levonorgestrel-only method. The levonorgestrel-only method uses levonorgestrel 1.5mg (as a single dose or as two 0.75mg doses 12 hours apart) taken within 3 days of unprotected sex, with one study indicating that beginning as late as 120 hours (5 days) after intercourse could be effective.
The primary mechanism of action of levonorgestrel as a progestogen-only emergency contraceptive pill is, according to FIGO, to prevent fertilization by inhibition of ovulation. The International Federation of Gynecology and Obstetrics(FIGO) has issued a statement that: "review of the evidence suggests that LNG [levonorgestreol] ECPs cannot prevent implantation of a fertilized egg. Language on implantation should not be included in LNG ECP product labeling." In June 2012, a New York Timeseditorial called on the Food and Drug Administration(FDA) to remove from the label the unsupported suggestion that levonorgestrel emergency contraceptive pills inhibit implantation. In November 2013, the European Medicines Agency(EMA) approved a change to the label for HRA Pharma's NorLevo saying it cannot prevent implantation of a fertilized egg. In November 2013, the EMA also approved a change to the label for HRA Pharma's NorLevo saying: "In clinical trials, contraceptive efficacy was reduced in women weighing 75 kg [165 pounds] or more, and levonorgestrel was not effective in women who weighed more than 80 kg [176 pounds]." In November 2013 and January 2014, the FDA and the EMA said they were reviewing whether increased weight and body mass index(BMI) reduce the efficacy of emergency contraceptives.
Levonorgestrel is also used in Intrauterine system, Contraceptive implants and Hormone replacement therapy.
